BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the publication of a scientific paper in the peer-reviewed international medical journal, Journal of Clinical Oncology.

Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading provider of advanced veterinary diagnostic and specialty products, plans to report its third quarter 2020 financial performance in a press release before the market opens on Thursday, November 5, 2020 and to host an earnings call to discuss the results followi

Beckman Coulter, a global clinical diagnostics leader, today announced that it was awarded funding by the Biomedical Advanced Research and Development Authority (BARDA) part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services,

entrinsic bioscience (EBS) , a company pioneering a next generation protein modulation technology, today announced that it has been granted U.S. Patent No. (USPN) 10,758,507 (‘507 patent) for novel therapeu

- Lambda significantly accelerated viral decline - Viral clearance highly correlated with baseline viral loads - All Lambda-treated patients were below the infectivity threshold by Day 7

Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be featured at the North America Conference on Lung Cancer being held October 16-17.

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

Plus Therapeutics, Inc., announced that it has been invited to participate in the Cancer Innovation Summit.

Clinically meaningful, dose-dependent, and statistically significant improvements in theCognitive Drug Research(CDR) computerized assessmentsystem analysis